These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 2405159)
1. Renin inhibitors containing isosteric replacements of the amide bond connecting the P3 and P2 sites. Kaltenbronn JS; Hudspeth JP; Lunney EA; Michniewicz BM; Nicolaides ED; Repine JT; RoarK WH; Stier MA; Tinney FJ; Woo PK J Med Chem; 1990 Feb; 33(2):838-45. PubMed ID: 2405159 [TBL] [Abstract][Full Text] [Related]
2. Renin inhibitors based on dipeptide analogues. Incorporation of the hydroxyethylene isostere at the P2/P3 sites. Kempf DJ; de Lara E; Stein HH; Cohen J; Egan DA; Plattner JJ J Med Chem; 1990 Jan; 33(1):371-4. PubMed ID: 2404121 [TBL] [Abstract][Full Text] [Related]
3. Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites. Raddatz P; Jonczyk A; Schmitges CJ; Sombroek J Adv Exp Med Biol; 1991; 306():387-90. PubMed ID: 1812733 [No Abstract] [Full Text] [Related]
4. Substrate analogue renin inhibitors containing replacements of histidine in P2 or isosteres of the amide bond between P3 and P2 sites. Raddatz P; Jonczyk A; Minck KO; Schmitges CJ; Sombroek J J Med Chem; 1991 Nov; 34(11):3267-80. PubMed ID: 1956045 [TBL] [Abstract][Full Text] [Related]
5. Novel small renin inhibitors containing 4,5- or 3,5-dihydroxy-2-substituted-6-phenylhexanamide replacements at the P2-P3 sites. Jung GL; Anderson PC; Bailey M; Baillet M; Bantle GW; Berthiaume S; Lavallée P; Llinas-Brunet M; Thavonekham B; Thibeault D; Simoneau B Bioorg Med Chem; 1998 Dec; 6(12):2317-36. PubMed ID: 9925293 [TBL] [Abstract][Full Text] [Related]
10. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin. Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938 [TBL] [Abstract][Full Text] [Related]
11. Specificity in the binding of inhibitors to the active site of human/primate aspartic proteinases: analysis of P2-P1-P1'-P2' variation. Rao CM; Scarborough PE; Kay J; Batley B; Rapundalo S; Klutchko S; Taylor MD; Lunney EA; Humblet CC; Dunn BM J Med Chem; 1993 Sep; 36(18):2614-20. PubMed ID: 8410973 [TBL] [Abstract][Full Text] [Related]
12. New inhibitors of human renin that contain novel replacements at the P2 site. Doherty AM; Kaltenbronn JS; Hudspeth JP; Repine JT; Roark WH; Sircar I; Tinney FJ; Connolly CJ; Hodges JC; Taylor MD J Med Chem; 1991 Apr; 34(4):1258-71. PubMed ID: 1901910 [TBL] [Abstract][Full Text] [Related]
13. New inhibitors of renin that contain novel phosphostatine Leu-Val replacements. Dellaria JF; Maki RG; Stein HH; Cohen J; Whittern D; Marsh K; Hoffman DJ; Plattner JJ; Perun TJ J Med Chem; 1990 Feb; 33(2):534-42. PubMed ID: 2105396 [TBL] [Abstract][Full Text] [Related]
14. Aminoethylenes: a tetrahedral intermediate isostere yielding potent inhibitors of the aspartyl protease BACE-1. Yang W; Lu W; Lu Y; Zhong M; Sun J; Thomas AE; Wilkinson JM; Fucini RV; Lam M; Randal M; Shi XP; Jacobs JW; McDowell RS; Gordon EM; Ballinger MD J Med Chem; 2006 Feb; 49(3):839-42. PubMed ID: 16451048 [TBL] [Abstract][Full Text] [Related]
15. Renin inhibitors containing psi[CH2O] pseudopeptide inserts. TenBrink RE; Pals DT; Harris DW; Johnson GA J Med Chem; 1988 Mar; 31(3):671-7. PubMed ID: 3279210 [TBL] [Abstract][Full Text] [Related]
16. NEW RENIN-INHIBITORS--STABILITY AND ACTIVITY DETERMINATION. PART III. Marszałek D; Goldnik A; Winiecka I; Jaworski P; Mazurek AP Acta Pol Pharm; 2016; 73(2):329-36. PubMed ID: 27180425 [TBL] [Abstract][Full Text] [Related]